Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 1860

 

Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Advertise Contacts Login 
     
CASE REPORT
Year : 2015  |  Volume : 56  |  Issue : 1  |  Page : 74-76

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm


Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria

Correspondence Address:
Abdulaziz Hassan
Department of Haematology, Ahmadu Bello University Teaching Hospital, PMB 06 Shika, Zaria 810001, Kaduna State
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0300-1652.149177

Rights and Permissions

The World Health Organisation (WHO) classifies myeloproliferative neoplasm (MPN) into BCR-ABL positive chronic myeloid leukaemia (CML Ph + ) and Ph MPN. The JAK2 V617F mutation is specific for Ph MPN and occurs in approximately 50% of primary myelofibrosis. Earlier reports suggest that the occurrence of JAK2 and BCR-ABL mutations are mutually exclusive. However, recent reports have documented the coexistence of BCR-ABL and JAK2 mutation in the same patient mostly following treatment with tyrosine kinase inhibitors (TKIs). We thus report a 60-year-old male with atypical clinical and laboratory features of MPN and the presence of both BCR-ABL and JAK2 Mutations.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2295    
    Printed40    
    Emailed0    
    PDF Downloaded125    
    Comments [Add]    
    Cited by others 7    

Recommend this journal